However, in a pre-specified analysis of a PD-L1-positive TNBC cohort (PD-L1 positivity is defined by PD-L1 expression on tumor-infiltrating immune cells that cover ≥ 1% of the tumor area), the addition of atezolizumab to nab-paclitaxel significantly improved median PFS of 7.4 months versus 4.8 months, respectively (HR 0.60; 95% CI, 0.48–0.77; p < 0.0001), and a larger benefit on OS of 25 months versus 15.5 months, respectively (HR, 0.62; 95% CI, 0.45–0.86) when compared to the chemotherapy (nab-paclitaxel)-alone arm. The gene discussed is CD274; the disease is neoplasm.